Journal of Digestive Cancer Reports

Korean Society of Gastrointestinal Cancer Research (대한소화기암연구학회)
권호 표지

Aspirin and Non-steroidal Anti-inflammatory Drugs in Prevention of Gastric Cancer

아스피린 및 비스테로이드 소염제와 위암의 예방

  • Kim, Yeon-Ji (Department of Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea College of Medicine) ;
  • Chung, Woo Chul (Department of Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea College of Medicine)
  • 김연지 (가톨릭대학교 의과대학 내과학교실 성빈센트병원 소화기내과) ;
  • 정우철 (가톨릭대학교 의과대학 내과학교실 성빈센트병원 소화기내과)
  • Received : 2020.10.21
  • Accepted : 2020.11.16
  • Published : 2020.12.31

⟨ Previous Next ⟩

Abstract

Gastric cancer is one of the leading causes of cancer-related deaths worldwide. The increased expression of cyclooxygenase (COX)-2 has been implicated in the development and progression of gastric cancers. A number of recent studies have been published evaluating the chemopreventive effect of aspirin and non steroidal anti inflammatory drungs (NSAIDs) against gastric cancer. Aspirin and NSAIDs use may reduce the risk of gastric cancer incidence and death, whereas other studies have reported contradictory results. Therefore, further study should be needed to clarify the role of aspirin and NSAIDs in the chemoprevention of gastric cancer.

Keywords

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 2018;68:394-424. https://doi.org/10.3322/caac.21492
  2. Abramson S, Weissmann G. The mechanisms of action of nonsteroidal antiinflammatory drugs. Clinical and Experimental Rheumatology 1989;7:S163-170.
  3. Chen C-N, Sung C-T, Lin M-T, Lee P-H, Chang K-J. Clinicopathologic association of cyclooxygenase 1 and cyclooxygenase 2 expression in gastric adenocarcinoma. Annals of Surgery 2001;233:183. https://doi.org/10.1097/00000658-200102000-00006
  4. Seibert K, Zhang Y, Leahy K, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proceedings of the National Academy of Sciences 1994;91:12013-12017. https://doi.org/10.1073/pnas.91.25.12013
  5. Cosme R, Lublin D, Takafuji V, Lynch K, Roche JK. Prostanoids in human colonic mucosa: effects of inflammation on PGE2 receptor expression. Human Immunology 2000;61:684-696. https://doi.org/10.1016/S0198-8859(00)00131-2
  6. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. The Lancet Oncology 2012;13:518-527. https://doi.org/10.1016/S1470-2045(12)70112-2
  7. Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G. Aspirin, salicylates, and cancer. The Lancet 2009;373:1301-1309. https://doi.org/10.1016/S0140-6736(09)60243-9
  8. Narisawa T, Sato M, Tani M, Kudo T, Takahashi T, Goto A. Inhibition of development of Methylinitrosourea-induced rat colon tumors by Indomethacin treatment. Cancer Research 1981;41:1954-1957.
  9. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Research 1988;48:4399-4404.
  10. Tsuji S, Kawano S, Sawaoka H, et al. Evidences for involvement of cyclooxygenase-2 in proliferation of two gastrointestinal cancer cell lines. Prostaglandins, Leukotrienes and Essential fatty acids 1996;55:179-183. https://doi.org/10.1016/S0952-3278(96)90095-2
  11. Joo Y-E, Chung I-J, Park Y-K, et al. Expression of cyclooxygenase-2, p53 and Ki-67 in gastric cancer. Journal of Korean Medical Science 2006;21:871-876. https://doi.org/10.3346/jkms.2006.21.5.871
  12. Uefuji K, Ichikura T, Shinomiya N, Mochizuki H. Induction of apoptosis by JTE-522, a specific cyclooxygenase-2 inhibitor, in human gastric cancer cell lines. Anticancer research 2000;20:4279.
  13. Zhou XM, Wong BCY, Fan XM, et al. Non-steroidal anti-inflammatory drugs induce apoptosis in gastric cancer cells through up-regulation of bax and bak. Carcinogenesis 2001;22:1393-1397. https://doi.org/10.1093/carcin/22.9.1393
  14. Jiang X-H, Lam S-K, Lin MC, et al. Novel target for induction of apoptosis by cyclo-oxygenase-2 inhibitor SC-236 through a protein kinase C-β 1-dependent pathway. Oncogene 2002;21:6113-6122. https://doi.org/10.1038/sj.onc.1205778
  15. Sawaoka H, Kawano S, Tsuji S, et al. Helicobacter pylori infection induces cyclooxygenase-2 expression in human gastric mucosa. Prostaglandins, Leukotrienes and Essential Fatty Acids 1998;59:313-316. https://doi.org/10.1016/S0952-3278(98)90079-5
  16. Romano M, Ricci V, Memoli A, et al. Helicobacter pylori up-regulates cyclooxygenase-2 mRNA expression and prostaglandin E2 synthesis in MKN 28 gastric mucosal cells in vitro. Journal of Biological Chemistry 1998;273:28560-28563. https://doi.org/10.1074/jbc.273.44.28560
  17. Uefuji K, Ichikura T, Mochizuki H, Shinomiya N. Expression of cyclooxygenase-2 protein in gastric adenocarcinoma. Journal of surgical oncology 1998;69:168-172. https://doi.org/10.1002/(SICI)1096-9098(199811)69:3<168::AID-JSO9>3.0.CO;2-0
  18. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer ㄲesearch 1998;58:2929-2934.
  19. Chae SW, Sohn JH, Shin HS, Park YE. Expression of cyclooxygenase-2 protein in gastric carcinogenesis. Cancer Research and Treatment 2002;34:252-257. https://doi.org/10.4143/crt.2002.34.4.252
  20. Lehnert T, Deschner EE, Karmali RA, DeCosse JJ. Effect of flurbiprofen and 16, 16-dimethyl-prostaglandin E2 on gastrointestinal tumorigenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in rats. I. Squamous epithelium and mesenchymal tissue. Journal of the National Cancer Institute 1987;78:923-929.
  21. Bespalov V, Troian D, Petrov A, Morozov V, Khavinson V. In- hibiting effect of thymogen on the development of tumors of the esophagus and forestomach induced by N-nitrososarcosine ethyl ester in rats. Eksperimental'naia Onkologiia 1989;11:23.
  22. Fu S-L, Wu Y-L, Zhang Y-P, Qiao M-M, Chen Y. Anti-cancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer. World journal of gastroenterology: WJG 2004;10:1971. https://doi.org/10.3748/wjg.v10.i13.1971
  23. Hu P, Yu J, Zeng Z, et al. Chemoprevention of gastric cancer by celecoxib in rats. Gut 2004;53:195-200. https://doi.org/10.1136/gut.2003.021477
  24. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW. Aspirin use and risk of fatal cancer. Cancer Research 1993;53:1322-1327.
  25. Sorensen HT, Friis S, Norgard B, et al. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. British Journal of Cancer 2003;88:1687-1692. https://doi.org/10.1038/sj.bjc.6600945
  26. Cook NR, Lee I-M, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005;294:47-55. https://doi.org/10.1001/jama.294.1.47
  27. Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, HAWK E. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Research 2004;24:3177-3184.
  28. Epplein M, Nomura AM, Wilkens LR, Henderson BE, Kolonel LN. Nonsteroidal antiinflammatory drugs and risk of gastric adenocarcinoma: the multiethnic cohort study. American Journal of Epidemiology 2009;170:507-514. https://doi.org/10.1093/aje/kwp162
  29. Abnet C, Freedman N, Kamangar F, Leitzmann M, Hollenbeck A, Schatzkin A. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. British Journal of Cancer 2009;100:551-557. https://doi.org/10.1038/sj.bjc.6604880
  30. Tian W, Zhao Y, Liu S, Li X. Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer. European Journal of Cancer Prevention 2010;19:288-298. https://doi.org/10.1097/CEJ.0b013e328339648c
  31. Kim Y-I, Kim SY, Kim JH, et al. Long-term low-dose aspirin use reduces gastric cancer incidence: a nationwide cohort study. Cancer Research and Treatment: Official Journal of Korean Cancer Association 2016;48:798. https://doi.org/10.4143/crt.2015.117
  32. Niikura R, Hirata Y, Hayakawa Y, Kawahara T, Yamada A, Koike K. Effect of aspirin use on gastric cancer incidence and survival: A systematic review and meta-analysis. JGH Open 2020;4:117-125. https://doi.org/10.1002/jgh3.12226
  33. Bosetti C, Santucci C, Gallus S, Martinetti M, La Vecchia C. Aspirin and the risk of colorectal and other digestive tract cancers: an updated meta-analysis through 2019. Annals of Oncology 2020.
  34. Akre K, Ekstrom A, Signorello L, Hansson L, Nyren O. Aspirin and risk for gastric cancer: a population-based case-control study in Sweden. British Journal of Cancer 2001;84:965-968. https://doi.org/10.1054/bjoc.2001.1702
  35. Wu C-Y, Wu M-S, Kuo KN, Wang C-B, Chen Y-J, Lin J-T. Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients. Journal of Clinical Oncology 2010;28:2952-2957. https://doi.org/10.1200/JCO.2009.26.0695
  36. Leung WK, Ng EK, Chan FK, et al. Effects of long-term rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial. Clinical Cancer Research 2006;12:4766-4772. https://doi.org/10.1158/1078-0432.ccr-06-0693
  37. Wong BC, Zhang L, Ma J-l, et al. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut 2012;61:812-818. https://doi.org/10.1136/gutjnl-2011-300154